The increlex market research report is one of a series of new reports that provides increlex market statistics, including the increlex industry's global market size, regional shares, competitors with an increlex market share, detailed increlex market segments, market trends and opportunities, and any further data you may need to thrive in the increlex industry. This increlex market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to rising demand for effective treatments for growth hormone insensitivity, increasing adoption of personalized medicine, rising clinical trials to expand therapeutic applications, rising regulatory approvals for innovative formulations, growing healthcare infrastructure in emerging economies, and rising awareness about pediatric growth disorders globally. Major trends in the forecast period include advancements in recombinant DNA technology, improvement in delivery systems for subcutaneous injections, advancements in patient monitoring solutions, integration of telemedicine for patient follow-up, and advancements in drug delivery systems.
The growing prevalence of childhood-onset growth hormone deficiency (CGHD) is expected to drive the growth of the increlex market. CGHD occurs when the body does not produce enough growth hormone during childhood, resulting in slower growth and shorter stature. Factors such as advancements in diagnostic methods and increased awareness of the condition have contributed to the rise in CGHD cases. As awareness and diagnosis of CGHD increase, the demand for Increlex, a synthetic IGF-1 treatment, is also growing, as more children are receiving the necessary therapy. For example, in November 2023, the Council of Health Insurance in Saudi Arabia estimated that childhood-onset growth hormone deficiency affects between 1 in 3,500 and 1 in 10,000 children, with boys being more commonly affected. This increase in CGHD prevalence is driving the expansion of the increlex market.
Rising healthcare expenditure is anticipated to propel the growth of the increlex market as well. Healthcare expenditure refers to the total financial resources spent on medical services, treatments, medications, and hospital care over a specific period. Factors such as an aging population, increased healthcare needs, advancements in medical technology, and rising service and medication costs are contributing to the rise in healthcare spending. As healthcare expenditure increases, access to advanced treatments such as increlex becomes more widely available, further driving market growth. For instance, a report from the Office for National Statistics in May 2024 showed a 5.6% increase in total healthcare expenditure in the UK from 2022 to 2023, compared to a mere 0.9% growth in 2022. This rising healthcare expenditure is expected to boost the increlex market.
In October 2024, Eton Pharmaceuticals Inc., a US-based pharmaceutical company, acquired increlex (mecasermin injection) from Ipsen S.A. for an undisclosed amount. Ipsen will continue to distribute Increlex for six months before Eton assumes responsibility for global commercialization. This acquisition will allow Eton to expand its portfolio while ensuring that access to Increlex remains uninterrupted. Ipsen S.A., a pharmaceutical company based in France, specializes in the development of drugs such as Increlex.
The key company operating in the increlex market is Ipsen S.A.
North America was the largest region in the increlex market in 2024. The regions covered in increlex report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the increlex market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Increlex is the brand name for mecasermin, a recombinant human insulin-like growth factor-1 (rhIGF-1). It is used to treat growth failure in children with severe primary IGF-1 deficiency or those whose bodies do not produce enough insulin-like growth factor-1 (IGF-1), a crucial hormone for normal growth.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary age group for Increlex includes infants, toddlers, and children aged 5-12 years. Pediatric patients diagnosed with severe primary IGF-1 deficiency (SPIGFD), a rare growth disorder where the body lacks sufficient IGF-1 despite having adequate growth hormone levels, are the main users of Increlex. Mecasermin works by mimicking IGF-1 to address this deficiency, helping to improve growth rates and other developmental outcomes. Increlex is distributed through various channels, such as hospitals, specialty clinics, online pharmacies, and retail pharmacies. Its applications include treating growth hormone deficiency and related conditions.
The increlex market consists of sales of increlex injectable solution, increlex pre-filled syringes, and increlex vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to rising demand for effective treatments for growth hormone insensitivity, increasing adoption of personalized medicine, rising clinical trials to expand therapeutic applications, rising regulatory approvals for innovative formulations, growing healthcare infrastructure in emerging economies, and rising awareness about pediatric growth disorders globally. Major trends in the forecast period include advancements in recombinant DNA technology, improvement in delivery systems for subcutaneous injections, advancements in patient monitoring solutions, integration of telemedicine for patient follow-up, and advancements in drug delivery systems.
The growing prevalence of childhood-onset growth hormone deficiency (CGHD) is expected to drive the growth of the increlex market. CGHD occurs when the body does not produce enough growth hormone during childhood, resulting in slower growth and shorter stature. Factors such as advancements in diagnostic methods and increased awareness of the condition have contributed to the rise in CGHD cases. As awareness and diagnosis of CGHD increase, the demand for Increlex, a synthetic IGF-1 treatment, is also growing, as more children are receiving the necessary therapy. For example, in November 2023, the Council of Health Insurance in Saudi Arabia estimated that childhood-onset growth hormone deficiency affects between 1 in 3,500 and 1 in 10,000 children, with boys being more commonly affected. This increase in CGHD prevalence is driving the expansion of the increlex market.
Rising healthcare expenditure is anticipated to propel the growth of the increlex market as well. Healthcare expenditure refers to the total financial resources spent on medical services, treatments, medications, and hospital care over a specific period. Factors such as an aging population, increased healthcare needs, advancements in medical technology, and rising service and medication costs are contributing to the rise in healthcare spending. As healthcare expenditure increases, access to advanced treatments such as increlex becomes more widely available, further driving market growth. For instance, a report from the Office for National Statistics in May 2024 showed a 5.6% increase in total healthcare expenditure in the UK from 2022 to 2023, compared to a mere 0.9% growth in 2022. This rising healthcare expenditure is expected to boost the increlex market.
In October 2024, Eton Pharmaceuticals Inc., a US-based pharmaceutical company, acquired increlex (mecasermin injection) from Ipsen S.A. for an undisclosed amount. Ipsen will continue to distribute Increlex for six months before Eton assumes responsibility for global commercialization. This acquisition will allow Eton to expand its portfolio while ensuring that access to Increlex remains uninterrupted. Ipsen S.A., a pharmaceutical company based in France, specializes in the development of drugs such as Increlex.
The key company operating in the increlex market is Ipsen S.A.
North America was the largest region in the increlex market in 2024. The regions covered in increlex report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the increlex market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Increlex is the brand name for mecasermin, a recombinant human insulin-like growth factor-1 (rhIGF-1). It is used to treat growth failure in children with severe primary IGF-1 deficiency or those whose bodies do not produce enough insulin-like growth factor-1 (IGF-1), a crucial hormone for normal growth.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary age group for Increlex includes infants, toddlers, and children aged 5-12 years. Pediatric patients diagnosed with severe primary IGF-1 deficiency (SPIGFD), a rare growth disorder where the body lacks sufficient IGF-1 despite having adequate growth hormone levels, are the main users of Increlex. Mecasermin works by mimicking IGF-1 to address this deficiency, helping to improve growth rates and other developmental outcomes. Increlex is distributed through various channels, such as hospitals, specialty clinics, online pharmacies, and retail pharmacies. Its applications include treating growth hormone deficiency and related conditions.
The increlex market consists of sales of increlex injectable solution, increlex pre-filled syringes, and increlex vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Increlex Market Characteristics4. Increlex Market Trends And Strategies5. Increlex Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Increlex Pricing Analysis & Forecasts30. Global Increlex Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Increlex Market32. Recent Developments In The Increlex Market
3. Increlex Market Biologic Drug Characteristics
6. Global Increlex Growth Analysis And Strategic Analysis Framework
8. Increlex Market Segmentation
9. Global Increlex Epidemiology Of Clinical Indications
10. Increlex Market Regional And Country Analysis
11. Asia-Pacific Increlex Market
12. China Increlex Market
13. India Increlex Market
14. Japan Increlex Market
15. Australia Increlex Market
16. South Korea Increlex Market
17. Western Europe Increlex Market
18. UK Increlex Market
19. Germany Increlex Market
20. France Increlex Market
21. Eastern Europe Increlex Market
22. North America Increlex Market
23. USA Increlex Market
24. Canada Increlex Market
25. South America Increlex Market
26. Middle East Increlex Market
27. Africa Increlex Market
28. Increlex Market Competitive Landscape And Company Profiles
29. Global Increlex Market Pipeline Analysis
33. Increlex Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Increlex Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on increlex market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for increlex ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The increlex market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Age Group: Infants, Toddlers, Children Aged 5-12 Years2) By Distribution Channel: Hospitals; Specialty Clinics; Online Pharmacies; Pharmacies
3) By Application: Growth Hormone Deficiency; Other Indications
Key Companies Profiled: Ipsen S.A
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Ipsen S.A